Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
FERGUS v. IMMUNOMEDICS, INC. et al
Case Number:
2:16-cv-03335
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
Companies
Sectors & Industries:
-
January 20, 2023
NJ Judge Signs Off On $1.3M Atty Fee In Immunomedics Suit
The attorneys who represented investors in a class action against a New Jersey pharmaceutical company have won a $1.33 million fee award for the suit, which was based on allegedly broken promises the company made about how it would present new information about a drug.
-
April 15, 2022
Biotech Co. To Pay $4M To End Presentation Hype Suit
A biopharmaceutical company acquired by Gilead Sciences will pay $4 million to resolve class claims in New Jersey federal court alleging it misled investors into expecting that new drug results would be presented at conferences of the American Society of Clinical Oncology, according to a motion seeking preliminary approval of the deal.
-
June 01, 2020
Immunomedics Must Face Suit Over Drug Presentation Claims
A New Jersey federal judge on Monday refused to toss a proposed class action against Immunomedics Inc. after concluding that a shareholder had improved his complaint alleging the biopharmaceutical company misled investors into expecting it would present new drug results at upcoming conferences of the American Society of Clinical Oncology.
-
April 01, 2019
BioPharma Co. Ducks Stock-Drop Suit Over Presentation Hype
Immunomedics Inc. has at least temporarily dodged a stock-drop suit accusing it of hyping investors on its planned presentation at the 2016 American Society of Clinical Oncology's annual meeting only for the company's event to be canceled.
-
June 10, 2016
Investor Sues Immunomedics Over Cancer Drug Misstatements
An investor for clinical-stage biopharmaceutical company Immunomedics Inc. on Thursday filed a putative class action against the company, alleging that misstatements about its eligibility to present research about trials for a breast and lung cancer treatment at a conference led to a drop in stock prices.